Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Expanded FDA Approval Improves Care Access, Rates of Flu Cases

Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at SeqirusGregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means for care access, and how they foresee this new indication improving rates of flu in the future. 

 

Advertisement

Advertisement